All contents ©2010 ALP Life Sciences, LLC. All rights reserved.
Use of this site signifies acceptance of Terms and Conditions
Use of this site signifies acceptance of Terms and Conditions
ALP Life Sciences, LLC is dedicated to commercialization of products to treat fatty liver diseases and related inflammatory diseases. The Nanoveson™ project is focused on a new discovery in lipid research.
The Company is pursuing FDA regulatory approvals for Nanoveson™ therapy, a proposed method of treatment for non-alcoholic fatty liver disease (NAFLD). The next indication targets for Nanoveson™ are additional fatty liver related diseases, including non-alcoholic steatohepatitis (NASH).
The novel Nanoveson™ mechanism of action is expected to have an impact on inflammatory diseases, potentially including asthma, arthritis, cardiovascular disease and cancer. The science also has potential application for diagnostics and drug metabolism testing.
The Nanoveson™ whitepaper presents the science behind the new discovery and proposed lipid therapy. Please contact us if you are interested in learning more.